(EMAILWIRE.COM, November 13, 2019 ) The increasing prevalence of chronic diseases, increasing R&D spending, and increasing healthcare spending are the major factors driving the growth of the market. The base year considered for the study is 2017 and the forecast period includes 2018 to 2023.

Market Size
The global Immunofluorescence Assay Market is expected to reach USD 2.01 Billion by 2023 from an estimated USD 1.51 Billion in 2018, at a CAGR of 5.8%.

To know about the assumptions considered for the study download the pdf brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=255585571

“By product, the reagents segment accounted for the largest share of the immunofluorescence assay market in 2017.”
On the basis of product, the reagents segment accounted for the largest share of the global immunofluorescence assay market. The large share of this segment is due to growing applications of biosciences and biotechnology within the pharmaceutical and healthcare fields, the rising prevalence of a number of diseases, growing R&D activities, and government initiatives to strengthen national research capabilities are driving the growth of the reagents segment.

“The cancer segment holds the largest share in 2017”
Based on disease, the cancer segment accounted for the largest share of the immunofluorescence assay market. The large share of this segment can be attributed to the fact that the increasing prevalence of cancer across the globe and the widespread adoption of immunofluorescence techniques for the study and diagnosis of cancer.

Recent Developments
• In 2016, the company launched Evos FL Auto 2 Imaging System. In the same year, the company also signed an agreement with EUROIMMUN (Germany).
• In 2017, the company launched QUANTA-Lyser 3000. In the same year, the company again launched two NOVA Lite reagents.

For More Details, Request Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=255585571